CHICAGO — Surgical revascularization led to fewer major adverse limb events and deaths compared with endovascular therapy in patients with chronic limb-threatening ischemia, according to the prospective randomized BEST-CLI trial.
After a median follow-up of 2.7 years, the primary composite outcome of major adverse limb events and death from any cause occurred in 42.6% of patients who had an adequate great saphenous vein available for surgery (cohort 1) compared with 57.4% who were assigned to endovascular therapy (HR 0.68, 95% CI 0.59-0.79, P